Postauricular gentamicin administration does not provide preferential inner-ear delivery in guinea pigs
- 1Department of Otorhinolaryngology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China
- 2Department of Otolaryngology Head and Neck Surgery, Zhuhai People’s Hospital, Zhuhai, Guangdong, China
- 3Center for Hearing and Deafness, Department of Communicative Disorders and Sciences, University at Buffalo, Amherst, New York, United States
Abstract
Background: Whether postauricular injection provides preferential access to the inner ear relative to conventional systemic administration remains uncertain. We used gentamicin as an ototoxic model drug to compare postauricular, intramuscular and intratympanic injection through a surgically created posterior tympanotomy in guinea pigs.
Methods: Forty-eight male guinea pigs were studied in repeated-dose and single-dose experiments. In the repeated-dose experiment, gentamicin was administered postauricularly or intramuscularly every 12 h for 7 days (14 injections). Auditory brainstem response (ABR) thresholds, cochlear outer hair cells (OHC), body weight, serum creatinine, and blood urea nitrogen were assessed. In the single-dose experiment, animals received gentamicin by intratympanic injection through a posterior tympanotomy, postauricular injection, or intramuscular injection. OHC morphology and perilymph gentamicin concentrations were evaluated at 2.5 and 12.5 h.
Results: Repeated postauricular and intramuscular administration produced comparable bilateral ABR threshold elevations and extensive OHC loss, together with body-weight reduction and renal dysfunction; no significant between-route differences were detected for these outcomes. At 12.5 h after a single administration, moderate OHC loss was observed only after intratympanic injection. Perilymph gentamicin concentrations at 2.5 h were 4,103 ± 349 μg/mL after intratympanic injection, 18.43 ± 4.70 μg/mL after postauricular administration, and 21.84 ± 16.75 μg/mL after intramuscular administration. At 12.5 h, the respective concentrations were 416.20 ± 109.10, 10.86 ± 5.98, and 11.58 ± 7.88 μg/mL. Postauricular and intramuscular concentrations did not differ significantly at either time point.
Conclusions: Postauricular gentamicin injection did not provide preferential access to the inner ear compared with intramuscular injection. Under the conditions of this guinea pig model, its cochlear and systemic effects were consistent with systemic exposure rather than targeted local delivery that bypassed the blood–labyrinth barrier (BLB).
Related
- Oromucosal administration of oxytocin and its receptor antagonist atosiban respectively increase and decrease preferential attention to dynamic social stimuli in men
- Lipid-ASO therapeutics exhibit differential tissue targeted delivery upon systemic or local CNS administration
- Gentamicin impairs nephron development in iPSC-derived kidney organoids and disrupts proximal tubular lysosomal function
- Gentamicin-Augmented Intrarenal Irrigation During Percutaneous Nephrolithotomy Reduces 30-Day Infectious Complications and Eliminates Pyelonephritis and Sepsis: A 1:2 Matched Cohort Study
- Immunohistochemical Insights into Enhanced Burn Wound Healing by Poly(vinyl alcohol)/Gentamicin and Poly(vinyl alcohol)/Chitosan/Gentamicin Hydrogels.
BibTeX
@article{chen2026postauricular,
title = {{Postauricular gentamicin administration does not provide preferential inner-ear delivery in guinea pigs}},
author = {Dan Chen and Liling Li and Jia Luo and Jingqian Tan and Xuexin Lin and Dalian Ding and Peng Li},
journal = {PeerJ},
year = {2026},
month = oct,
doi = {10.7717/peerj.21796},
url = {https://peerj.com/articles/21796},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Postauricular gentamicin administration does not provide preferential inner-ear delivery in guinea pigs
AU - Dan Chen
AU - Liling Li
AU - Jia Luo
AU - Jingqian Tan
AU - Xuexin Lin
AU - Dalian Ding
AU - Peng Li
PY - 2026
DA - 2026/10/27
JO - PeerJ
DO - 10.7717/peerj.21796
UR - https://peerj.com/articles/21796
AB - Background: Whether postauricular injection provides preferential access to the inner ear relative to conventional systemic administration remains uncertain. We used gentamicin as an ototoxic model drug to compare postauricular, intramuscular and intratympanic injection through a surgically created posterior tympanotomy in guinea pigs. Methods: Forty-eight male guinea pigs were studied in repeated-dose and single-dose experiments. In the repeated-dose experiment, gentamicin was administered postauricularly or intramuscularly every 12 h for 7 days (14 injections). Auditory brainstem response (ABR) thresholds, cochlear outer hair cells (OHC), body weight, serum creatinine, and blood urea nitrogen were assessed. In the single-dose experiment, animals received gentamicin by intratympanic injection through a posterior tympanotomy, postauricular injection, or intramuscular injection. OHC morphology and perilymph gentamicin concentrations were evaluated at 2.5 and 12.5 h. Results: Repeated postauricular and intramuscular administration produced comparable bilateral ABR threshold elevations and extensive OHC loss, together with body-weight reduction and renal dysfunction; no significant between-route differences were detected for these outcomes. At 12.5 h after a single administration, moderate OHC loss was observed only after intratympanic injection. Perilymph gentamicin concentrations at 2.5 h were 4,103 ± 349 μg/mL after intratympanic injection, 18.43 ± 4.70 μg/mL after postauricular administration, and 21.84 ± 16.75 μg/mL after intramuscular administration. At 12.5 h, the respective concentrations were 416.20 ± 109.10, 10.86 ± 5.98, and 11.58 ± 7.88 μg/mL. Postauricular and intramuscular concentrations did not differ significantly at either time point. Conclusions: Postauricular gentamicin injection did not provide preferential access to the inner ear compared with intramuscular injection. Under the conditions of this guinea pig model, its cochlear and systemic effects were consistent with systemic exposure rather than targeted local delivery that bypassed the blood–labyrinth barrier (BLB).
SN - 2167-8359
ER -